Clostridium difficile colitis
MONDO:0000705A bacterial infection of the colon secondary to infection with Clostridium difficile bacteria. This infection generally results from the loss of normal gut flora secondary to recent antibiotic use, and manifests as copious watery stools, with associated abdominal pain and myalgia. C. difficile is the most common cause of pseudomembranous colitis, and can progress to toxic megacolon if left untreated.
Also known as: C. diff colitis, C. diff infection, Clostridioides difficile caused colitis (disease), Clostridioides difficile colitis (disease), Clostridium difficile infection, pseudomembranous colitis
121 clinical trials for this condition and its sub-types, 69 tagged with Clostridium difficile colitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for recurring c. diff: which treatment works best?
Disease control Stopped earlyThis study tested three different antibiotic regimens for people with recurrent Clostridium difficile infection (C. diff), a serious gut infection that keeps coming back. The goal was to see if newer drugs like fidaxomicin or a tapered/pulsed course of vancomycin work better than…
Phase 4 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Promising c. diff drug fails to prove benefit in small, halted trial
Disease control Stopped earlyThis study tested whether an extra dose of bezlotoxumab, a drug that blocks the harmful toxin made by C. diff bacteria, could help very sick patients recover after emergency colon surgery. Only 5 people took part before the study was stopped early. The goal was to see if the drug…
Phase 4 • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising c. diff drug trial halted after just 3 patients
Disease control Stopped earlyThis study tested a new drug called REC-3964 to see if it could prevent repeat Clostridioides difficile (C. diff) infections in adults. Only 3 people were enrolled before the trial was stopped early. The goal was to check safety and whether the drug helped people stay infection-f…
Phase 2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Antibiotic teicoplanin tested for stubborn gut infection
Disease control Stopped earlyThis study tested the antibiotic teicoplanin (taken by mouth twice daily for 7 to 14 days) in 50 adults hospitalized with C. difficile infection causing diarrhea and colitis. The goal was to see if it could stop diarrhea and prevent it from coming back. The trial was terminated e…
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC